The selective BTK inhibitor acalabrutinib (Calquence) will be listed on the PBS from 1 September for the second line treatment of chronic lymphocytic leukaemia (CLL) and small lymphocytic lymphoma. About 1600 patients are expected to gain subsidised access to AstraZeneca’s acalabrutinib which would otherwise cost more than $140,000 per course of treatment, following a positive ...
Acalabrutinib gets PBS listing for r/r CLL and SLL
By Michael Woodhead
31 Aug 2020